摘要
目的观察小儿消积止咳口服液联合孟鲁司特钠和特布他林治疗儿童慢性咳嗽变异性哮喘(cough variant asthma,CVA)的临床疗效。方法选取2018年1月—2022年1月60例在南京市江宁区中医院儿科门诊、住院的CVA患儿,按照随机数表法分为治疗组和对照组,每组30例,对照组给予雾化特布他林、口服孟鲁司特钠咀嚼片,治疗组在对照组治疗基础上给予口服小儿消积止咳口服液,3次/d,15~20 mL/次,将连续治疗14 d临床疗效、不良事件发生率记录整理数据并统计分析。结果治疗后治疗组患儿嗜酸性粒细胞(EOS)、超敏C反应蛋白(hs-CRP)水平均明显低于对照组,差异有统计学意义(P<0.05);治疗后治疗组患儿的咳嗽缓解时间短于对照组,差异有统计学意义(P<0.05);治疗组治疗有效率高于对照组,差异有统计学意义(P<0.05);两组患儿在治疗过程中不良事件的发生率比较,差异无统计学意义(P>0.05)。结论小儿消积止咳口服液联合孟鲁司特钠和特布他林治疗儿童CVA,可以更有效地降低血液炎性指标,更快地改善咳嗽症状,治疗过程中的不良事件发生率未升高,值得临床应用。
Objective To observe the clinical eff ect of xiaoer Xiaoji cough oral liquid combined with Montelukast sodium and Terbutaline in the treatment of chronic cough variant asthma CVA in children.Methods From January 2018 to December 2022,sixty patients with CVA were selected and randomly divided into treatment group and control group,with 30 Datients in each group.The control group was given atomized terbutaline,oral Montelukast sodium chewable tablets.On the basis of control group,xiaoer Xiaoji cough oral liquid was added to the treatment group,3 times/day,15~20 mL/time,for 14 consecutive days.The percentage of eosinophil granulosis(EOS),the level of hypersensitive C-reactive protein(hs-CRP),the duration of cough remission,clinical efficacy,and the incidence of adverse events were recorded and statistically analyzed before and after treatment.Results After treatment,EOS and hs-CRP in the treatment group were significantly lower than those in the control group(P<0.05).After treatment,the remission time of cough in treatment group was shorter than that in control group,and the diff erence was statistically significant(P<0.05).The eff ective rate of treatment group was higher than control group,and the diff erence was statistically significant(P<0.05).There was no significant diff erence in the incidence of adverse events between the two groups(P>0.05).Conclusion Pediatric xiaoer Xiaoji cough oral liquid combined with Montelukast sodium and Terbutaline in the treatment of children's CVA can more eff ectively reduce blood inflammation indicators,improve cough symptoms faster,the incidence of adverse events during the treatment process did not increase,which is worthy of further clinical recommendation.
作者
顾芙蓉
范海婷
GU Fu-rong;FAN Hai-ting(Department of Pediatrics,Jiangning Traditional Chinese Medicine Hospital,Nanjing Jiangsu 211100,China;Pharmacy Department of Yancheng Dexin Hospital,Yancheng Jiangsu 224001,China)
出处
《中华养生保健》
2023年第23期31-35,共5页
CHINESE HEALTH CARE
